Our Portfolio


Advancing state-of-the-art precision medicine.

We envision a world where people are enabled to make better choices for a better life.

Existing precision medicines target just 10% of cancers – those with DNA mutations in oncogenic drivers for a small number of genes. OncXerna is transforming precision medicine beyond single genetic mutations by discovering the dominant biology of a person’s cancer at the RNA level to advance more meaningful treatments for more cancer patients.

Arctic Vision

Arctic Vision is a China-based clinical stage specialty ophthalmology company with a leading portfolio of breakthrough technologies. The Company’s vision is to address ophthalmology’s unmet needs through innovative therapies in China, Asia and globally. Arctic Vision is established by top-tier life sciences investors and led by an elite team of ophthalmic industry veterans with substantial and compelling China and global experiences in R&D and commercialization of eye care products.


Acquiring, developing and commercializing transformative medicines in neuroscience.

We aim to become an elite innovative neuroscience company addressing China specific unmet medical needs with top notch development and commercial capabilities.

We aspire to bridge the gap of innovative neuroscience treatments between China and global leaders by bringing their breakthrough therapies to make patient lives better in China and Asia.

We are led by a world-class neuroscience veteran team with proven track records and repeated successes in developing and commercializing CNS drugs in China and Asia.

We are backed by top-tier biotech venture capitals with broad network worldwide, in-depth knowledge and unprecedent track records in new venture incubation in China.

Visen Pharma

VISEN Pharmaceuticals is committed to the treatment of endocrine-related diseases, introducing the world's leading treatment methods and drugs into the China market, and hoping to provide more Chinese patients quick access to the world's most advanced and reliable treatment solutions.

Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company based in the USA and China committed to becoming a leader in the development and delivery of immune-based therapies for patients in need. Zenas is rapidly advancing a deep portfolio of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. At Zenas, we strive to be a truly innovative company. Our vision is to be a global leader in bringing innovative immune-based medicines to patients in the US, China and around the world. We are guided by our core value system: TRUE Innovation.

Ablaze Pharma

Ablaze Pharma is a clinical stage Biopharmaceutical Company that is focused on developing Targeted Radiotherapy (TRT) to benefit cancer patients in China. We leverage our founders' extensive business experience and network in cross-border product development and deal making to bring innovative TRT products to China's market. We strive to become the leader and the partner of choice in the emerging TRT market in China by working together with our strategic business partners in both China and abroad.

SanReno Therapeutics

SanReno Therapeutics is a joint venture focusing on nephrology and related therapeutic areas. Pivotal bioVenture Partners China jointly established SanReno in China together with Frazier Healthcare Partners, a well-known US life science fund, and Chinook Therapeutics, a clinical-stage biotechnology company. SanReno is led by pharmaceutical veterans from the top tier management team, such as Baxter, Novartis and etc. SanReno is committed to providing world-leading innovative treatments and clinical solutions to create better quality of life for more patients.